Implementation of Transdx Group for POTS

September 24, 2019 updated by: University of Colorado, Denver

Implementation of a Transdiagnostic Psychological Group Intervention for Pediatric Autonomic Dysfunction

The proposed intervention is focused on developing and implementing a psychological approach incorporated into a group-based outpatient intervention for pediatric autonomic dysfunction. The investigators hypothesize that their intervention will result in improvements in the transdiagnostic mechanisms specifically targeted by components of their intervention including sleep, information processing, and youth/parent experiential avoidance.

Study Overview

Status

Completed

Study Type

Interventional

Enrollment (Actual)

16

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Colorado
      • Aurora, Colorado, United States, 80045
        • Children's Hospital Colorado

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

11 years to 16 years (Child, Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adolescent participants must be

    1. between the ages of 13-18 years old,
    2. english speaking, and
    3. have been diagnosed with autonomic dysfunction, dysautonomia, orthostatic intolerance, and/or POTS.
  • Participants must also:

    1. endorse symptoms of autonomic dysfunction on the COMPASS 31 (measures are described below), and show
    2. moderate functional impairment, and/or
    3. some psychiatric symptoms in the domains of anxiety and/or depression.
  • FDI scores must be greater than 12 (see Kashikar-Zuck et al., 2011 for an empirical rationale).
  • Must have attended at least one day of school per week during the past month.
  • On the measures of anxiety (SCARED) and depression (CDI), the adolescent's scale score must be above the "average" range based on T scores (CDI) or within the "clinical" range (SCARED).
  • Each participant must have at least one English-speaking parent/legal guardian who can provide informed consent for the adolescent, as well as participate in the study.
  • Each adolescent and their parent/legal guardian(s) must be English-speaking.

Exclusion Criteria:

  • Adolescent participants;

    1. wards of the state,
    2. endorse active homicidal or suicidal ideation,
    3. have an intellectual disability, a pervasive developmental disability or significant developmental delay,
    4. endorse an active substance use disorder, and
    5. are currently participating in individual or group psychotherapy.
    6. do not have in-network health insurance that covers Health and Behavior interventions, or
    7. are unable to self-pay.
  • Parent/legal guardian(s) are

    1. unwilling to participate in the study,
    2. are non-English speaking, or
    3. have an intellectual disability, a pervasive developmental disability or significant developmental delay, and/or
    4. do not have legal custody of the adolescent participant.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group Intervention
10-week parent-child multi-family group
10 week 90-minute weekly therapy sessions including both the adolescent and caregiver. Treatment will consist of psychoeducation about dysautonomia, motivational interviewing techniques to promote readiness for change, support around lifestyle and behavioral changes, core CBT components (e.g., relaxation training, linking thoughts, feelings, and behaviors, minimizing catastrophizing thoughts, cognitive coping, and exposure), and components of ACT aiming to increase cognitive flexibility (e.g., mindfulness, experiential avoidance, values, cognitive defusion, committed action), and relapse prevention and maintenance. Most sessions will involve homework assigned to the adolescent and their parent/legal guardian(s) to encourage practice at home.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Composite Autonomic Symptom Score (self-report)
Time Frame: Baseline, 10 weeks, and 6-months
This is a 31 item self-report measure developed to assess autonomic symptoms (e.g., dizziness, orthostatic intolerance, nausea, sweating).
Baseline, 10 weeks, and 6-months
Change in Functional Disability Inventory (caregiver and self-report)
Time Frame: Baseline, 10 weeks, and 6-months
This is a measure that evaluates children's difficulty in physical and psychosocial functioning due to their physical health. The instrument consists of 15 items that assess self-perceptions of activity limitations during the past 2 weeks.
Baseline, 10 weeks, and 6-months
Change in Children's Depression Inventory (caregiver and self-report)
Time Frame: Baseline, 10 weeks, and 6-months
This is a 27-item self-report measure designed to assess cognitive, behavioral, and affective symptoms of depression.
Baseline, 10 weeks, and 6-months
Change in Screen for Childhood Anxiety Related Emotional Disorders (caregiver and self-report)
Time Frame: Baseline, 10 weeks, and 6-months
This measure is used to screen for childhood anxiety disorders including general anxiety disorder, separation anxiety disorder, panic disorder and social phobia. In addition, it assesses symptoms related to school refusal. The SCARED consists of 41 items.
Baseline, 10 weeks, and 6-months
Change in Transdiagnostic Youth/Parent Questionnaire
Time Frame: Baseline, 10 weeks, and 6-months
Our team developed these comprehensive questionnaires to assess transdiagnostic mechanisms in the present study. These questionnaires comprise full measures and/or subscales drawn from several well-validated and psychometrically-sound measures that are available as part of the public domain and/or that were provided for open access by the developers of the measure, and that have been previously designed and validated to measure each of the mechanisms of interest. These mechanisms include emotion regulation, experiential avoidance, sleep, peer acceptance/rejection, parenting, and information processing.
Baseline, 10 weeks, and 6-months
Change in Pain Coping Questionnaire (caregiver and self-report)
Time Frame: Baseline, 10 weeks, and 6-months
For the current study, this measure has been adapted to ask about "physical illness symptoms" rather than pain. The adapted measure asks adolescents/caregivers to indicate how often (1 = never to 5 = very often) they/their child used each of 39 coping strategies when responding to prompts such as, "When I am experiencing autonomic symptoms for a few hours or days, I…"
Baseline, 10 weeks, and 6-months
Satisfaction Questionnaire (caregiver and self-report)
Time Frame: 10 weeks
This is an 8-item measure intended to assess satisfaction, perceived benefits, and likelihood of recommending the program. Items, which include "How would you rate the quality of care you have received?" are rated on a 1 to 4 Likert-scale.
10 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Jessica Malmberg, PhD, University of Colorado/Children's Hospital Colorado

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 26, 2017

Primary Completion (Actual)

March 1, 2019

Study Completion (Actual)

September 1, 2019

Study Registration Dates

First Submitted

June 8, 2017

First Submitted That Met QC Criteria

June 9, 2017

First Posted (Actual)

June 14, 2017

Study Record Updates

Last Update Posted (Actual)

September 26, 2019

Last Update Submitted That Met QC Criteria

September 24, 2019

Last Verified

September 1, 2019

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depression

Clinical Trials on Transdiagnostic Group-Based Treatment

3
Subscribe